Almirall, S.A. (LBTSF.PK), a biopharmaceutical company, on Monday reported higher profit for the first nine months of 2025, mainly driven by growth in sales.
Net income for the 9-month period surged to €39.1 million from €7.2 million in the same period last year.
EBITDA, or earnings before interest, taxes, depreciation, and amortization rose 27.1% year-on-year to €180.7 million.
Revenue increased 12.9% to €825.6 million from €731.2 million last year, with net sales growth of 12.8% to €820.7 million.
For the full year 2025, the company continues to expect net sales growth of between 10% and 13%, and EBITDA in the range of €220 million to €240 million.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.